BCL9 and acute lymphoblastic leukemia: Upon the completion of all analysis and validation steps, we assigned the samples to the following BCP-ALL subgroups: BCR-ABL1 (Ph)-like (n = 31), DUX4-positive (n = 16), ETV6-RUNX1-like (n = 3), IKZF1 (p.N159Y) (n = 1), KMT2A-rearranged (n = 6), MEF2D-BCL9 (n = 3), NUTM1-rearranged (n = 4), PAX5 (p.P80R) (n = 6), PAX5 alt (n = 6), TCF3-HLF (n = 1), TCF3-PBX1 (n = 1), ZNF384-rearranged and like (n = 10) and iAMP21 (n = 3), while 84 samples remained unassigned at this point (Table S2).